Home » Citing India and China Competition, DSM to Close Intermediates Business
Citing India and China Competition, DSM to Close Intermediates Business
DSM Specialty Intermediates B.V. in Sittard (Netherlands) announced the intention to discontinue its operational activities by 31 December 2010 at the latest. As a consequence, DSI's production activities at the Chemelot industrial site in Sittard-Geleen will be stopped with effect from 1 July 2010. The closure will result in the loss of 37 jobs at DSI. DSM strives to avoid forced redundancies as much as possible. DSM has asked the local Works Council for advice on the intended closure.
DSI produces and sells intermediates for the automotive, food and pharmaceutical industries. Due in particular to increasing competition from China and India, among other countries, prices and margins for these products have been under heavy pressure for a number of years.
For this reason, a number of DSI production plants had already been closed in 2007 and the remaining facilities had been integrated with other DSM plants in order to make the business unit financially healthy. Despite the strong efforts of DSI's management and workforce, it proved impossible to make DSI structurally profitable, even after these measures.
Given this situation, the only option left is to close DSI. Therefore, the intention is to discontinue all operational activities by 31 December 2010 at the latest. In connection with this, the production activities will be stopped earlier, with effect from 1 July 2010, after which the product stocks will be used to meet the remaining supply obligations.
DSI employs 37 people, who will lose their jobs as a result of the closure. The aim is to offer these employees an alternative within DSM. Employees for whom no alternative job can be found will be declared redundant at the moment when their job ceases to exist. The DSM LBV Supervision of Employment Plan as agreed with the trade unions at DSM Limburg BV will apply to all employees who will become redundant as a result of the closure.
French Drugmaker on Trial for Suspected DeathsFrom Yahoo! News
Servier Laboratories, French drugmaker responsible for producing diabetes and weight loss drug Mediator, faces charges for deception in relation to the suspected deaths of hundreds of people.
Novo Acquires Xellia Pharmaceuticals for $700 MillionFrom PharmaTimes Online
Novo A/S has acquired Xellia Pharmaceuticals of Norway
Royalty Increases Bid as Elan Unveils AcquisitionsFrom PharmaTimes Online
Royalty Pharma has resurfaced to raise its bid to acquire the Irish drugmaker Elan
New Asthma Drug Offers Hope for PatientsFrom Forbes
An experimental asthma drug could give new hope to patients for whom existing medicines are not enough
Syrian Pharma Production Nearly Halted by WarFrom AFP
A shortage of foreign currency has brought production to a near halt in Syria
Camfil APC Opens Manufacturing Plant in the UKFrom Camfil
Camfil announced the grand opening of its new 40,000-sq.-ft. facility
Actavis Acquiring Warner Chilcott for $8.5BFrom AP
Actavis to buy Warner Chilcott in an all-stock transaction
Northwest Analytics Launches Next Generation Enterprise Manufacturing Intelligence SolutionFrom Northwest Analytics
NWA Focus EMI Delivers Real Time Process Intelligence and Unique Accelerating Modules - a Shared Knowledge Base and Manufacturing-Centric Collaboration
Innovative Clinical Development Partnership Announced By Quintiles and Merck SeronoFrom MarketWatch.com
Agreement creates unique strategic collaboration for development and clinical trial execution
$15 Billion Myland Offer Rejected By ActavisFrom Bloomberg.com
Actavis has rejected drugmaker Mylan Inc's cash-and-stock offer for $15 billion. They have decided to continue talks to take over Warner Chilcott Plc instead, sources have said.
- All news »